Literature DB >> 15954198

Increased nitric oxide radicals in postmortem brain from patients with schizophrenia.

Jeffrey K Yao1, Sherry Leonard, Ravinder D Reddy.   

Abstract

Alterations in antioxidant status in schizophrenia suggest free radical-mediated neurotoxicity; this finding can be a consequence of increased free radical production. There are multiple pathways to excess free radical generation and subsequent oxidative stress. One such pathway is the formation of peroxynitrite by a reaction of nitric oxide (NO) and superoxide radical. NO is formed from L-arginine by nitric oxide synthase (NOS). A constitutive cytosolic isoform, neuronal NOS (nNOS), appears to be fairly stable in the postmortem brain tissues. Utilizing a sensitive fluorometric assay, NO levels were measured by its stable metabolites, nitrate and nitrite, in the caudate region of postmortem brain tissues from patients and control subjects. In the human brain, NO is metabolized primarily in the form of nitrate. A significantly increased level of NO was found in schizophrenia patients (241 +/- 146 pmol/mg dry weight, n = 18) than was found in those of normal (142 +/- 65 pmol/mg dry weight, n = 20) and psychiatric controls without schizophrenia (125 +/- 83 pmol/mg dry weight, n = 16) (analysis of covariance [ANCOVA], F = 6.446, df = 2,51, p = 0.003). These findings were independent of age, brain weight, postmortem interval (PMI), sample storage time, or cigarette smoking. Elevated NO levels in the brains of schizophrenia patients lend further support for the free radical pathology in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15954198     DOI: 10.1093/oxfordjournals.schbul.a007142

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  36 in total

1.  Oxidative stress in schizophrenia: pathogenetic and therapeutic implications.

Authors:  Jeffrey K Yao; Ravinder Reddy
Journal:  Antioxid Redox Signal       Date:  2011-05-04       Impact factor: 8.401

2.  Imbalanced free radicals and antioxidant defense systems in schizophrenia: a comparative study.

Authors:  Hui-chun Li; Qiao-zhen Chen; Ying Ma; Jun-fu Zhou
Journal:  J Zhejiang Univ Sci B       Date:  2006-12       Impact factor: 3.066

Review 3.  Oxidative stress in schizophrenia: an integrated approach.

Authors:  Byron K Y Bitanihirwe; Tsung-Ung W Woo
Journal:  Neurosci Biobehav Rev       Date:  2010-10-23       Impact factor: 8.989

Review 4.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

5.  Critical role of nitric oxide on nicotine-induced hyperactivation of dopaminergic nigrostriatal system: Electrophysiological and neurochemical evidence in rats.

Authors:  Vincenzo Di Matteo; Massimo Pierucci; Arcangelo Benigno; Ennio Esposito; Giuseppe Crescimanno; Giuseppe Di Giovanni
Journal:  CNS Neurosci Ther       Date:  2010-03-25       Impact factor: 5.243

6.  Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia.

Authors:  Jeffrey K Yao; George G Dougherty; Ravinder D Reddy; Matcheri S Keshavan; Debra M Montrose; Wayne R Matson; Joseph McEvoy; Rima Kaddurah-Daouk
Journal:  PLoS One       Date:  2010-03-03       Impact factor: 3.240

7.  Impaired metabolic reactivity to oxidative stress in early psychosis patients.

Authors:  Margot Fournier; Carina Ferrari; Philipp S Baumann; Andrea Polari; Aline Monin; Tanja Bellier-Teichmann; Jacob Wulff; Kirk L Pappan; Michel Cuenod; Philippe Conus; Kim Q Do
Journal:  Schizophr Bull       Date:  2014-03-31       Impact factor: 9.306

8.  Evidence for the contribution of NOS1 gene polymorphism (rs3782206) to prefrontal function in schizophrenia patients and healthy controls.

Authors:  Zhifang Zhang; Xiongying Chen; Ping Yu; Qiumei Zhang; Xiaochen Sun; Huang Gu; Hao Zhang; Jinguo Zhai; Min Chen; Boqi Du; Xiaoxiang Deng; Feng Ji; Chuanyue Wang; Yutao Xiang; Dawei Li; Hongjie Wu; Jun Li; Qi Dong; Chuansheng Chen
Journal:  Neuropsychopharmacology       Date:  2014-12-10       Impact factor: 7.853

9.  No association between polymorphisms of neuronal oxide synthase 1 gene (NOS1) and schizophrenia in a Japanese population.

Authors:  Takenori Okumura; Tomo Okochi; Taro Kishi; Masashi Ikeda; Tsuyoshi Kitajima; Yoshio Yamanouchi; Yoko Kinoshita; Kunihiro Kawashima; Tomoko Tsunoka; Hiroshi Ujike; Toshiya Inada; Norio Ozaki; Nakao Iwata
Journal:  Neuromolecular Med       Date:  2009-06-10       Impact factor: 3.843

10.  Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia.

Authors:  Borja García-Bueno; Miquel Bioque; Karina S Mac-Dowell; M Fe Barcones; Monica Martínez-Cengotitabengoa; Laura Pina-Camacho; Roberto Rodríguez-Jiménez; Pilar A Sáiz; Carmen Castro; Amalia Lafuente; Javier Santabárbara; Ana González-Pinto; Mara Parellada; Gabriel Rubio; M Paz García-Portilla; Juan A Micó; Miguel Bernardo; Juan C Leza
Journal:  Schizophr Bull       Date:  2013-03-13       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.